06.10.14
Just in time for the beginning of its Phase II ALS trial, BrainStorm Cell Therapeutics Inc. has appointed Tony Fiorino, M.D., Ph.D. as its new CEO.
Fiorino, 46, brings to BrainStorm broad and extensive experience in both biotechnology finance and drug development. Prior to joining BrainStorm, he was a managing director at Greywall Asset Management, a healthcare equity fund. Previously, Fiorino was founder, president and CEO of EnzymeRx, where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through Phase 1/2 clinical trials and its subsequent sale to 3SBio. Before founding EnzymeRx, Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup, and Pequot Capital. Fiorino earned an M.D. and a Ph.D. from the Albert Einstein College of Medicine, where he studied the differentiation of liver progenitor cells, and a BS from the Massachusetts Institute of Technology.
“I am incredibly excited to be joining BrainStorm at this crucial juncture, with the company on the verge of launching a Phase II clinical trial in amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s Disease, at several prestigious academic medical centers in the Unites States,” said Fiorino. “BrainStorm also has an array of interesting pre-clinical data that will lead to additional clinical development programs. I look forward to leading BrainStorm and its research and development activities both in Israel and the US, as well as establishing and growing the company’s U.S. presence.”
“We are delighted to have Fiorino on board and warmly welcome him to BrainStorm,” said President Chaim Lebovits. “His diverse experience and successful track record attest to a deep understanding of the key aspects of biopharmaceutical development -- clinical, regulatory, and financial. The unique combination of expertise he brings with him promises to be a major asset to BrainStorm in the coming years,” he added.
BrainStorm Cell Therapeutics Inc. is an Israeli biotechnology company that makes adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The company has U.S. offices in New York, N.Y.
Fiorino, 46, brings to BrainStorm broad and extensive experience in both biotechnology finance and drug development. Prior to joining BrainStorm, he was a managing director at Greywall Asset Management, a healthcare equity fund. Previously, Fiorino was founder, president and CEO of EnzymeRx, where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through Phase 1/2 clinical trials and its subsequent sale to 3SBio. Before founding EnzymeRx, Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup, and Pequot Capital. Fiorino earned an M.D. and a Ph.D. from the Albert Einstein College of Medicine, where he studied the differentiation of liver progenitor cells, and a BS from the Massachusetts Institute of Technology.
“I am incredibly excited to be joining BrainStorm at this crucial juncture, with the company on the verge of launching a Phase II clinical trial in amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s Disease, at several prestigious academic medical centers in the Unites States,” said Fiorino. “BrainStorm also has an array of interesting pre-clinical data that will lead to additional clinical development programs. I look forward to leading BrainStorm and its research and development activities both in Israel and the US, as well as establishing and growing the company’s U.S. presence.”
“We are delighted to have Fiorino on board and warmly welcome him to BrainStorm,” said President Chaim Lebovits. “His diverse experience and successful track record attest to a deep understanding of the key aspects of biopharmaceutical development -- clinical, regulatory, and financial. The unique combination of expertise he brings with him promises to be a major asset to BrainStorm in the coming years,” he added.
BrainStorm Cell Therapeutics Inc. is an Israeli biotechnology company that makes adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The company has U.S. offices in New York, N.Y.